10.36

0.34% -0.0286

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $10.36, with a volume of 242.35K. It is down -0.34% in the last 24 hours and up +2.22% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Previous Close:

$10.39

Open:

$10.5

24h Volume:

242.35K

Relative Volume:

0.22

Market Cap:

$780.89M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-3.2789

EPS:

-3.16

Net Cash Flow:

$-176.27M

1W Performance:

+10.16%

1M Performance:

+2.22%

6M Performance:

-6.37%

1Y Performance:

+19.85%

1-Day Range:

$10.29

$10.69

1-Week Range:

$9.2606

$10.69

52-Week Range:

$6.44

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1165)

Industry

Biotechnology (652)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

479

Twitter

@Replimune

Next Earnings Date

2025-02-11

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	10.37	780.89M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	481.09	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	557.88	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	320.95	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	561.17	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	251.19	28.51B	3.81B	-644.79M	-669.77M	-6.24

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

Jun 17, 2025

GAMMA Investing LLC Boosts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 17, 2025

Jun 14, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE - Defense World

Jun 14, 2025

Jun 12, 2025

California State Teachers Retirement System Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 12, 2025

Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 15,402 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 11, 2025

Jun 08, 2025

Squarepoint Ops LLC Cuts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 08, 2025

Jun 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 07, 2025

Jun 06, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REPL Stock News - GuruFocus

Jun 06, 2025

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan - Nasdaq

Jun 06, 2025